Brandywine Global Investment Management LLC Buys 568,319 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Brandywine Global Investment Management LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 330.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 740,097 shares of the biopharmaceutical company's stock after acquiring an additional 568,319 shares during the quarter. Brandywine Global Investment Management LLC owned 0.06% of Gilead Sciences worth $68,363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. HHM Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences in the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter valued at $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC raised its stake in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ:GILD traded down $0.77 during mid-day trading on Tuesday, reaching $111.28. The company's stock had a trading volume of 6,284,006 shares, compared to its average volume of 7,301,817. The firm's fifty day moving average price is $105.88 and its two-hundred day moving average price is $95.20. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a market cap of $138.58 billion, a P/E ratio of 300.76, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences's dividend payout ratio is presently 854.05%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on GILD shares. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research report on Thursday, February 13th. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Bank of America lifted their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Finally, Morgan Stanley increased their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a report on Tuesday, March 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 302,785 shares of company stock valued at $30,503,250 over the last quarter. 0.16% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.